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Abstract
Background: Modifications in Pax6 homeogene expression produce strong eye phenotypes. This
suggested to us that eye development might be an appropriate model to verify if homeoprotein
intercellular passage has important functions in early development. Similar to other
homeoproteins, Pax6 has two domains that enable secretion and internalization by live cells and,
thus, intercellular passage. In principle, a straightforward way to test the hypothesis would be to
mutate one of the two sequences to produce a 'cell autonomous only' Pax6. However, this was not
possible because these sequences are in the homeodomain and their modification would affect
Pax6 transcriptional properties. We have thus developed an approach aimed at blocking Pax6 only
in the extracellular milieu of developing zebrafish embryos.
Results: A first strategy was to inject a one-cell embryo with a mRNA encoding a secreted single-
chain anti-Pax6 antibody. A second, complementary, strategy was to inject a Pax6 antibody in the
blastula extracellular milieu. In both cases, 'dissymmetric eyes', 'one eye only' and 'no eye'
phenotypes were produced. In most cases, lens phenotypes paralleled retina malformations.
Although eye phenotypes were analyzed 30 hours post-fertilization, there was a strong correlation
between early eye field asymmetry, early asymmetry in Pax6 expression and later-occurring eye
malformations. Several controls were introduced, demonstrating that the effect is specific to Pax6
and cannot be explained by intracellular antibody activities.
Conclusion: This study supports the hypothesis that the Pax6 transcription factor is also a
signaling molecule with direct non-cell autonomous activity.
Background
Eye formation is one of the most popular models used to
study the development and evolution of sensory systems
[1]. Similarities exist between vision apparatus across spe-
cies, leading to the two hypotheses of convergent evolu-
tion versus monophyletic origin [2]. This system is also
widely used for induction studies due to the inductive
interactions that take place between neural and non-neu-
ral tissues in the course of eye development. Spemann was
the first to propose that the interaction between the neural
fold and the surface ectoderm is at the origin of the induc-
tion of lens formation [3-5]. This induction between the
two tissues has been challenged and it has been hinted
that all species may not use identical strategies to develop
Published: 17 January 2007
Neural Development 2007, 2:2 doi:10.1186/1749-8104-2-2
Received: 3 August 2006
Accepted: 17 January 2007
This article is available from: http://www.neuraldevelopment.com/content/2/1/2
© 2007 Lesaffre et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Neural Development 2007, 2:2 http://www.neuraldevelopment.com/content/2/1/2
Page 2 of 12
(page number not for citation purposes)
a visual apparatus [6-8]. Although these evolutionary and
developmental issues are not fully resolved, it is now
largely accepted that certain shared genetic pathways play
important functions in the development of vision across
species.
The main breakthrough in the understanding of how the
eye has evolved and develops has come from genetic anal-
ysis, in particular the identification of Pax6 as a key tran-
scription factor for eye formation [9]. Indeed, Pax6 loss of
function, partial or total, leads to abnormal eye develop-
ment in all species, including human [2,10-12]. Con-
versely, excessively high expression leads to eye
malformation [13-16] or to the spectacular formation of
ectopic eyes [17,18]. The expression of Pax6 in the 'vision
apparatus' of all species, as well as the possibility to
induce eye formation in the fly by expressing vertebrate
Pax6, also strongly supports the idea that, in spite of mul-
tiple variations on the theme, there exists a common
genetic pathway in which Pax6 or Pax6-like genes play a
major role [19,20].
Interestingly, Pax6 is expressed in both neural and surface
epithelia that will give birth to retina proper and retina
pigmented epithelium (RPE) for the former and to lens
and cornea for the latter. This raises two main questions
regarding, firstly, the extent of the retina territory within
the neural fold and, secondly, the mechanisms of induc-
tion between the neural tissue and the surface epithelium
(lens induction). In both cases, it has been established
that the genetic pathways involve several transcription fac-
tors and growth factors of the Fibroblast Growth Factor
(FGF) and Bone Morphogenetic Protein (BMP) families
[5,21-26].
In the present study, we wanted to investigate the possibil-
ity that Pax6 could act as both a cell autonomous tran-
scription factor [5] and a non-cell autonomous signaling
factor [27,28] capable of inducing Pax6 expression after
intercellular passage [29-32]. The possibility that a tran-
scription factor could have both cell autonomous and
non-cell autonomous activity originates from the pres-
ence within the homeodomain of a majority of homeo-
protein transcription factors, including Pax6, of two short
sequences that enable secretion and internalization and,
thus, intercellular passage [33-35]. Based on the pheno-
types obtained following the in vivo expression of Pax6
antibodies in the intercellular space, we propose that, in
addition to other regular inducers and growth factors,
Pax6 acts as a signaling molecule during eye development.
Results
The presence within the Pax6 sequence of the two small
domains allowing homeoprotein internalization and
secretion (Figure 1a) [33] led us to investigate Pax6 inter-
cellular passage. As shown in Figure 1b–d, intercellular
transfer from Pax6-transfected COS cells towards HeLa
cells was verified by quantifying Pax6 detection within
recipient HeLa cells.
In principle, the most elegant way to identify homeopro-
tein non-cell autonomous activities in vivo would be to
replace the endogenous gene by a version mutated for
intercellular transfer. This is, unfortunately, impossible
because the two transport sequences that should be
mutated are within the DNA-binding domain (homeo-
domain), and thus also instrumental for cell autonomous
activities. This is why we developed a strategy based on the
possibility of using specific anti-Pax6 antibodies to trap
this transcription factor as it travels between cells.
We used the immunoglobulin light and heavy chains
expressed by the anti-Pax6 hybridoma to clone a cDNA
encoding an anti-Pax6 single chain antibody. Two ver-
sions were made, differing by the absence (aP6) or pres-
ence (spaP6) of a secretion signal peptide. As shown in
Figure 1f, spaP6 gains access to the Golgi and is present
within vesicles, thus showing a distribution strikingly dif-
ferent from that of its non-secreted counterpart, aP6,
which is detected throughout the cytoplasm (Figure 1e).
Figure 1e,f also illustrates that, in contrast to aP6, spaP6 is
absent from the nucleus, suggesting that very few anti-
body molecules, if any, escape from the secretion path-
way. To verify the transfer blocking activity of the
antibodies, we first added the monoclonal anti-Pax6 anti-
body, or a monoclonal anti-myc antibody as a control,
into the medium of co-cultured Pax6-expressing COS-7
cells and marked HeLa cells (see Materials and methods).
Figure 1g illustrates that anti-Pax6 antibodies in the cul-
ture medium significantly reduce intercellular transfer
between expressing and non-expressing cells, as com-
pared to control. We then co-cultured HeLa marked cells
with COS-7 cells co-expressing Pax6 and secreted single-
chain anti-Pax6 (spaP6) or anti-Engrailed (spaEn) anti-
bodies. Figure 1h illustrates that spaP6, and not spaEn,
blocks Pax6 transfer.
The monoclonal anti-Pax6 antibody had been produced
against the amino-terminal Pax6 domain, which is highly
conserved in all Pax6 sequences. Having verified that this
antibody recognizes zebrafish Pax6 proteins (not shown),
capped mRNAs encoding single chain antibodies were
injected into the zebrafish embryo at the one cell stage.
Eye morphologies observed 30 hours post-fertilization
(hpf) and induced by the secreted anti-Pax6 single-chain
antibody (spaP6) are illustrated in Figure 2a–f. The main
phenotype observed is a decrease in eye size, either sym-
metrical (as in Figure 2b) or asymmetrical (Figure 2c). In
extreme cases we noticed the absence of one eye (Figure
2d), or even of both eyes (Figure 2e). Cyclops were alsoNeural Development 2007, 2:2 http://www.neuraldevelopment.com/content/2/1/2
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Pax6 intercellular transfer is blocked by extracellular anti-Pax6 antibodies Figure 1
Pax6 intercellular transfer is blocked by extracellular anti-Pax6 antibodies. (a) Sequence alignment of Pax6 and En2 homeodo-
mains. Consensus amino acids are indicated in green letters between the two sequences; alpha helices are shaded. Amino acids 
involved in secretion and internalization are underlined (in red and blue, respectively). (b-d) COS-7 cells were transfected with 
a Pax6 expressing plasmid and co-cultured with HeLa cells marked by a GFP-H2b fusion. Pax6 transfer was monitored in every 
optical field by quantifying the Pax6 signal (overall signal shown in (b)) only in GFP-expressing HeLa cells (shown in (c)), giving 
(in (d)) the transfer signal as described in Materials and methods. Scale bar = 60 μm. (e,f) Subcellular localization of single-
chains aP6 (e) or spaP6 (f) transiently expressed in COS-7 cells. Schematic representations of the antibodies are presented: V-
k, kappa chain variable region; l, linker; V-H, heavy chain variable region; hm, his-myc tag. Whereas aP6 is detected throughout 
the cytoplasm and in the nucleus, spaP6 is restricted to vesicular structures and the Golgi apparatus (asterix). Scale bar = 10 
μm. (g,h) Inhibition of Pax6 intercellular transfer. (g) COS-7 cells expressing Pax6 were cultured together with HeLa cells in 
medium supplemented with anti-myc hybridoma (Hamyc) or anti-Pax6 hybridoma (HaP6). (h) COS-7 cells co-expressing Pax6 
and secreted single-chain antibodies against either Engrailed (spaEn) or Pax6 (spaP6) were cultured together with HeLa cells. In 
(g,h), Pax6 transfer to HeLa cells (analyzed as described in Materials and methods, in three independent experiments) was sig-
nificantly reduced by hybridoma addition (p < 0.015) or single-chain co-expression (p < 0.005).
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Eye phenotypes induced by secreted anti-Pax6 single-chain antibody Figure 2
Eye phenotypes induced by secreted anti-Pax6 single-chain antibody. (a-f) Eye phenotypes observed at 30 hpf after injection of 
secreted single-chain anti-Pax6 (spaP6) mRNA into one cell embryos. (a) Normal, (b) small eyes, (c) dissymmetric eyes, (d) 
single eye, (e) no eye, (f) cyclops. (g) Quantification (percentage) of phenotypes: n, normal; d, dissymmetric, reduced and 
absent eyes (pooled); c, cyclops. Comparison between secreted anti-Pax6 (spaP6, n = 221, red), secreted anti-En (spaEn, n = 
251, blue) and non-secreted anti-Pax6 (aP6, n = 178, dark red). Differences between spaP6 and spaEn or aP6, as well as 
between aP6 and spaEn, are statistically significant (p < 0.001, χ2 tests). (h) Quantification of single-chain mRNA expression. 
Top: western blot of protein extracts from embryos injected with the indicated RNAs (no : no RNA); the arrow indicates a 
single-chain antibody signal at approximately 34 kDa, and the arrowhead the cross-hybridizing protein species used for calibra-
tion. Bottom: densitometric scans of western signals indicate aP6 expression (ratio 1:1 with the endogenous signal) is at least as 
high as spaP6 expression (ratio 0.7:1 with the endogenous signal).
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observed (Figure 2f), but the percentage of animals with
this phenotype was similar, independent of the nature of
the mRNA injected in the egg (Figure 2g). In control
experiments (spaEn), 91% of the embryos had symmetri-
cal eyes, 3% showed dissymmetry and 6% were cyclops
(Figure 2g, left). In strong contrast, the in vivo expression
of spaP6 resulted in a ten-fold increase (40% of the
embryos) in the number of dissymmetric eyes or small
eyes, with no significant changes in the number of cyclops
(Figure 2g, right).
Because the latter eye phenotypes could result from the
cell autonomous activity of spaP6 antibodies escaping
from the secretion pathway, we compared the effects of
injecting spaP6 and aP6 capped mRNAs. Figure 2g (mid-
dle) shows that antibodies deprived of signal peptide also
have an effect on eye development, but that this effect
(15% of the embryos show eye dissymmetry) is signifi-
cantly smaller than that of secreted anti-Pax6. The signifi-
cant difference between aP6- and spaP6-induced
phenotypes did not result from differences in expression
as illustrated in Figure 2h, in which amounts of antibodies
expressed at gastrulation are compared. Most likely, the
difference between aP6- and spaP6-induced phenotypes is
due to the known instability of many intracellular anti-
bodies after disulfide bonds have been reduced by the
high intracellular glutathione content [36,37]. This series
of experiments thus strongly suggests that the eye pheno-
type observed after spaP6 mRNA injection reflects a
decrease in Pax6 direct non-cell autonomous activity.
To further verify the latter possibility, we injected the
hybridoma supernatant (HaP6) in the intercellular space
at the blastula stage. Using a fluorescein isothiocyanate
(FITC)-antibody, we first verified that antibodies injected
in the blastula diffuse between the cells and are not inter-
nalized (Figure 3a–d). The distribution of the antibody,
followed one hour after injection (Figure 3a,b) or at the
shield stage (Figure 3c,d), was predominantly, if not
exclusively, extracellular. We then injected HaP6 versus
vehicle, HaP6 versus HaMyc (anti-myc supernatant) or
HaP6 versus HaP6 pre-incubated with the epitope recog-
nized by the antibody (amino-terminal domain of Pax6).
Figure 3 illustrates the prototypic phenotypes that were
obtained (quantitative analysis in Figure 4) for three
embryos when HaP6 was injected at the blastula stage.
Eyes are either highly reduced or dissymmetric. Horizon-
tal sections (Figure 3g,j,m) confirm eye reduction and dis-
symmetry but also show that lenses are either absent
(Figure 3g) or smaller and/or displaced (Figure 3j,m).
Such phenotypes were never observed in any of the con-
trols and are similar to those observed after the injection
of capped spaP6 mRNAs into the egg.
The cumulative plots of eye sizes, not considering asym-
metry (all eyes are included, two eyes per animal) are pre-
sented in Figure 4. Clearly, HaP6 extracellular antibody
has a strong effect on eye size (Figure 4a) that cannot be
reproduced with the anti-myc antibody (Figure 4b). To
ascertain that this differential effect was not due to a dif-
ference in timing, we compared clutches in which the first
batch of embryos was injected either with the myc or with
the Pax6 antibody, and found no difference (compare Fig-
ure 4b and 4c). We also verified that pre-incubating the
antibody with the amino-terminal Pax6 epitope abol-
ished the effect on eye size distribution only when the
embryos were injected with anti-Pax6 antibodies (raised
against this epitope) (Figure 4d,e). This series of results
confirm those obtained with the single-chain encoding
mRNAs and strongly suggest that full eye development
requires extracellular Pax6 expression.
Figures 2, 3 and 4 illustrate and quantify the effect, at 30
hpf, of injections done much earlier, either at the one cell
stage (capped mRNA; Figure 2) or in the blastula (anti-
bodies; Figures 3 and 4). This does not allow one to verify
the stage at which the phenotypes first appear. To address
this point we analyzed different landmarks of the eye field
between 0 to 3 and 15 to 18 somite stages. At the earliest
stage (zero to three somites) no difference in Pax6 expres-
sion patterns was visible following HaP6 injection in the
blastula (Figure 5a–c). The same result was obtained with
Rx3, a more extensive marker of very early eye territory
(Figure 5d–f). In contrast, antagonizing Pax6 passage led
to a clear dissymmetry in Pax6 expression in the eye field
at the 12 to 15 (not shown) and 15 to 18 somite stages
(Figure 5g–i, blue arrows) but not, or not conspicuously,
in the other domains where Pax6 is also expressed, for
example, the diencephalon and hindbrain (d and h in Fig-
ure 5g'–i').
Finally, to verify if the early and late phenotypes were cor-
related, we observed the eye field of 48 embryos having
between 10 and 15 somites, when asymmetry is first visi-
ble in the eye field of embryos injected at the blastula
stage (Figure 5j–l), and followed the eye development of
each individual embryo. All embryos with normal and
symmetrical eye fields developed with normal eyes.
Among 15 embryos with small but symmetrical eye fields,
3 recovered completely, 3 matured with small eyes, 5 with
dissymmetric eyes and 4 lost both eyes completely. Of 15
embryos with dissymmetric eye fields, one developed two
small eyes, 2 matured with dissymmetric eyes and 12
developed no eye at all. Finally, out of 14 embryos with
no visible eye field, one developed asymmetric eyes and
the 13 others never developed any eye. We can thus con-
clude that the effect of the presence of anti-Pax6 antibod-
ies in the intercellular space takes place early in
development, probably before the six somite stage, asNeural Development 2007, 2:2 http://www.neuraldevelopment.com/content/2/1/2
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Eye phenotypes induced by intercellular injection of anti-Pax6 monoclonal antibody Figure 3
Eye phenotypes induced by intercellular injection of anti-Pax6 monoclonal antibody. (a-d) Intercellular distribution of FITC-
labeled anti-mouse antibody injected at the blastula stage. Embryos were analyzed in toto (a,c) or using confocal microscopy 
(b,d) either 1 hour after injection (a,b) or at the shield stage (c,d). Note that the staining is concentrated in the intercellular 
space and is virtually absent from the cell interior. (e-m) Prototypical eye phenotypes (quantifications in Figure 4): Embryo 1 
(e-g) has a severely reduced right eye (lateral view (e)) compared with left eye (lateral view (f)) and no right retina or lens (sec-
tion in (g)). Embryo 2 (h-j) has a strongly reduced left eye (frontal view in (h), lateral view in (i)). The horizontal section (j) con-
firms the phenotypes and indicates that the left lens is also reduced (arrow). Embryo 3 has two reduced eyes with disorganized 
morphologies (lateral views in (k,l)) and a reduced and misplaced left lens (red arrow in (l,m)). In all horizontal sections, rostral 
is to the left.
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Quantification and specificity of monoclonal anti-Pax6 effects Figure 4
Quantification and specificity of monoclonal anti-Pax6 effects. Eye area (measured in arbitrary units using Lucia G software, and 
distributed among 12 classes) of embryos injected at the blastula stage and presented as cumulative frequency plots. Reagents 
were always compared pair-wise on a single clutch. (a) Monoclonal anti-Pax6 (HaP6, number of eyes measured n = 161) versus 
vehicle (phosphate-buffered saline (PBS), n = 164). (b) HaP6 injected first in one half of the clutch (n = 128) versus monoclonal 
anti-myc (Hamyc, n = 120) injected immediately after in the second half of the clutch. (c) Hamyc (n = 70) versus HaP6 (n = 98), 
injected in the reverse order to (b). (d) HaP6 (n = 216) versus HaP6 pre-incubated with the amino-terminal arm of Pax6 
(HaP6+Nter, n = 132). (e) HaP6 pre-incubated with the amino-terminal arm of Pax6 (HaP6+Nter, n = 198) versus Hamyc pre-
incubated with the amino-terminal arm of Pax6 (Hamyc+Nter, n = 138). Differences are statistically significant for (a-d) (p < 
0.0001, Mann-Whitney tests).
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Anti-Pax6 perturbs early Pax6 expression in the eye territory Figure 5
Anti-Pax6 perturbs early Pax6 expression in the eye territory. (a-i) Pax6 (a-c and g-i') or Rx3 (d-f) in situ hybridization (ISH). 
Zebrafish embryos were injected at the blastula stage with vehicle (phosphate-buffered saline (PBS) in (a,d,g,g',j) or monoclonal 
anti-Pax6 (b,c,e,f,h,i,h',i'). (g'-i') Lower magnification versions of (g-i). Arrows indicate symmetric (black) and asymmetric (blue) 
distributions. ISH was performed at 0 to 3 somites (a-f), or 15 to 18 somites (g-i'). (j-l) Eye fields were photographed on live 
embryos at about 10 somites, after injection at the blastula stage with PBS (j) or monoclonal anti-Pax6 (k,l). d, diencephalon; h, 
hindbrain; a, anterior; p, posterior. N = 36 (a); n = 97 (b,c); n = 25 (d); n = 144 (e,f); n = 23 (g); n = 43 (h,i); n = 25 (j); n = 48 
(k,l).
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soon as the optic vesicle starts to form. In addition, it
seems that the type of phenotype seen at an early stage is,
in general, confirmed by the abnormality seen at later
stages.
Discussion
In the present study we have verified that, as expected
from sequence analysis, Pax6 is capable of intercellular
transfer in vitro (Figure 1) [34,35]. Our in vivo results sup-
port the idea of a direct non-cell autonomous activity of
Pax6, but say nothing concerning the importance of its
capture by abutting cells. Although we favor the hypo-
thesis that the non-autonomous activity reported here
requires Pax6 internalization, we do not preclude the pos-
sibility of Pax6 also having, or only having, an extracellu-
lar activity not requiring internalization.
As already mentioned, because the sequences necessary
for homeoprotein transfer are in the homeodomain [33],
we could not modify them to generate transgenic animals
expressing 'cell autonomous only' proteins. This is why
we applied an extracellular antibody strategy. Because of
their sensitivity to intracellular glutathion, single chain
antibodies are often unstable within the cell and deprived
of strong intracellular activities [36,37].
Intracellular instability of single chain anti-Pax6 antibody
was indirectly confirmed by the present data, where single
chain antibodies devoid of signal peptide, and thus purely
intracellular, were far less active than the secreted ones,
though the two constructs encoded the same variable
domain sequences and were expressed to the same level
(Figure 2). This result makes it unlikely that the biological
effects of spaP6 (the secreted form) can be explained by
the escape of the antibody from the secretion pathway.
The latter point was further confirmed by the absence of
spaP6 in the nucleus of transfected cells (as opposed to
aP6) and by experiments in which the full antibody (from
the hybridoma used to clone aP6 and spaP6) was injected
in the blastula (Figure 3). The similarities in phenotypes
obtained with either strategy (expression or injection)
reinforce the interpretation that interfering with direct
non-cell autonomous Pax6 activity induces abnormal eye
development.
The eye phenotype was primarily a reduction in eye size,
from partial to total. This reduction was sometimes sym-
metrical but one eye was often more affected than the
other. A likely explanation is that expressed or injected
antibodies are not evenly distributed. Indeed, following
injection, the mRNAs could accumulate preferentially in
one blastomere or in only one of the first two blastomeres
if injected just before the first division. It is not unlikely,
in the case of antibody injection in the blastula, that the
concentration of antibodies is not homogeneous or does
not remain so. In fact, an uneven distribution is visible in
Figure 3d, which was taken at the shield stage (confocal
section made at 50% epiboly).
Also striking is the fact that a defect in the retina is often
accompanied by an absence of lens or the development of
a small and/or ectopic lens. The lens and retina pheno-
types could be independent since Pax6  is expressed in
both structures. Alternatively, a defect in the neural retina
may have consequences for lens induction or develop-
ment. In the context of a role of the retina in lens induc-
tion, we cannot preclude that Pax6 secretion between the
neural fold and the surface epithelium participates in lens
induction. This indeed does not eliminate the possibility
that classic inducers are under Pax6 cell autonomous tran-
scriptional control [5,21-26,38,39].
The first sign of antibody activity is the abnormal pattern
of Pax6 expression in the eye field (Figure 5h,i). Com-
pared to controls, the domain of Pax6  expression is
smaller on one or both sides. Several explanations seem
plausible that are not mutually exclusive. One is that Pax6
is a non-cell autonomous regulator of cell death/survival
[40] and that blocking its passage reduces eye size through
local cell death. A second is that Pax6 is a non-cell auton-
omous regulator of cell division and that blocking its pas-
sage blocks the number of progenitors in the eye field or
forces their premature differentiation [16,41,42]. A third
is that secreted Pax6 activates its own transcription, either
indirectly or after internalization and transport to the
nucleus, thus inducing the extension of the eye field [31].
The third possibility, which may provide a molecular
mechanism for the concept of homeogenetic induction
[43,44] is indeed compatible with the two others since the
induced Pax6 could then act as a cell-autonomous regula-
tor of cell survival, division or commitment. Although we
have, at this stage, no reason to exclude any scenario, non-
autonomous self-activation at the transcription level is
compatible with the fact that Pax6 activates its own tran-
scription [29-32].
Interestingly, many studies suggest that, early in develop-
ment, several homeoproteins act in pairs to position bor-
ders within the neuroepithelium. Among several
examples, it was shown that a quantitative disequilibrium
between Emx2 and Pax6 results in a change in the size of
primary sensory areas with no modification in the total
surface of the neuroepithelium [45-47]. The same obser-
vation was made for the position of the isthmus, which
depends on the respective levels of expression of Otx2 and
Gbx2 [48,49]. Given that, within a pair, each of these pro-
teins activates its own transcription and down-regulates
that of the other, the non-cell autonomous activity
described here might provide a parsimonious and simple
mechanism for establishing borders.Neural Development 2007, 2:2 http://www.neuraldevelopment.com/content/2/1/2
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At the low level of precision permitted by our biological
model, it seems that the antibodies only affected eye
development and not other structures where the transcrip-
tion factor is also expressed (Figure 5g–i). Similarly, the
anti-Engrailed single chain antibody, taken as a control,
had no visible influence on brain morphology (Figure
2g), even though Engrailed-1 and Engrailed-2 are two
secreted homeoproteins [35]. A possible explanation is
that the changes are too small to be really identified in our
experimental model, possibly because they happen later,
when the antibodies have already been degraded and
diluted. Another possibility is that redundant signaling
mechanisms have been selected that are capable of buffer-
ing the phenotype. If so, it could be that Pax6 and the eye
are particularly suitable to investigate this novel signaling
mechanism, not only because eyes are highly variable
structures but also because Pax6 is a major player in eye
induction and development, as demonstrated by the
development of eyes upon Pax6  expression in ectopic
localization, both in the fly and in the vertebrates [17,18].
To pursue this line of thought in an evolutionary context,
homeoprotein transfer may have been an early mode of
signal transduction used for the exchange of positional
information in the first multi-cellular organisms. Such a
system, in which homeoproteins act as morphogens,
would have progressively gained in robustness through
the recruitment of additional modes of signal transduc-
tion based on the interaction of growth factors and recep-
tors, possibly under homeoprotein transcriptional and
translational control. In support of this idea, it was
recently demonstrated that homeoprotein Engrailed-2
can guide the axons of retinal ganglion cells following its
internalization into the cones, where it regulates the trans-
lation of local mRNAs [50]. Engrailed may thus have been
used as a signaling molecule prior to the invention of clas-
sic signaling mechanisms, leading to its present capacity
to act as both a guidance molecule through translation
regulation and a transcription factor for the expression of
classic guiding cues [51-54]. We speculate that the same
concept could apply to other messenger homeoproteins,
including Pax6, and that this unforeseen Pax6 property
may participate in both the definition of the eye field and
the exchange of information between the retina and the
lens.
Conclusion
Expressing or addressing in vivo monoclonal antibodies
against Pax6 modifies the pattern of Pax6 expression in
the developing eye field and induces strong eye pheno-
types affecting the retina and the lens. Based on the fact
that Pax6 intercellular transfer is antagonized by the anti-
bodies, we propose that Pax6 has two activities. A first cell
autonomous activity, classically described for all tran-
scription factors, is responsible for the control of the dif-
ferentiation programs of the retina and lens, including the
synthesis of bona fide growth factors and receptors. A sec-
ond activity requiring Pax6 secretion is necessary for the
full development of the eye anlage and supports the idea
that several homeoproteins are morphogens with direct
non-cell autonomous activity.
Materials and methods
Plasmids and proteins
Single chain antibody recombinants were prepared from
total RNA of anti-Pax6 and anti-Engrailed 4G11 Hybrid-
oma obtained from the Developmental Studies Hybrid-
oma Bank (DSHB, University of Iowa and NICHD,
Department of Biological Sciences, Iowa City, IA, USA).
Cloning was achieved as in [55]. The coding sequences
were inserted in a derivative of pSecTagHygroB (Invitro-
gen, Cergy, France) to give psecaP6 and psec4G11, while
the signal peptide coding sequence was removed from
pCBaP6 and pCB4G11; the open reading frames were also
transferred downstream of the EF1a and T7 promoter (in
a derivative of pEF1mycHis; Invitrogen) to give pEFsaP6
and pEFs4G11 (with signal peptide) and pEFaP6 and
pEF4G11 (without signal peptide). The amino-terminal
domain of Pax6 (coding sequence taken from pmPax6, a
gift of T Czerny, Wien, Austria) was produced in bacteria
and purified using poly-histidine extension. Full-length
Pax6 protein, with a Hemaglutinin (HA) tag at its amino
terminus, was expressed in COS-7 cells from the
pCHAPax6 plasmid, under the control of the CMV pro-
moter. Nucleic acids and protein manipulations were per-
formed according to standard procedures. Construction
details are available upon request.
Intercellular transfer of Pax6
COS-7 cells, cultured in DMEM/F12 plus 10% fetal calf
serum, were transfected with pCHAPax6 and either
pEFs4G11 or pEFsaP6, using lipofectamin 2000 (Invitro-
gen). Six hours after transfection, cells were collected by
trypsin treatment and plated on coated glass coverslips
(15 μg/ml poly-ornithin) at a concentration of 2.5 × 103
cells/cm2  together with HeLa cells (clone H2b, stably
expressing a GFP-histone 2b fusion protein; a gift from Dr
Valérie Doye, Institut Curie, Paris, France) at a concentra-
tion of 17 × 103 cells/cm2. In case of COS-7 cells singly
transfected by pCHAPax6, anti-myc (9E10) or anti-Pax6
(both from DSHB) monoclonal antibodies were added (4
μg/ml) in the co-culture medium. After 24 hours, co-cul-
tures were processed for immunocytochemistry as fol-
lows. Cells were washed and fixed (ethanol:acetic acid
93:7, 5 minutes, -20°C) and Pax6 expression was detected
with an anti-Pax6 polyclonal antibody [56] followed by a
Cy3-anti-rabbit antibody (Jackson Laboratories, Newmar-
ket, UK). GFP was detected with an anti-GFP monoclonal
antibody (Santa Cruz, Heidelberg, Germany) followed byNeural Development 2007, 2:2 http://www.neuraldevelopment.com/content/2/1/2
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an Alexa 488 anti-mouse antibody (Molecular Probes,
Cergy, France).
Transfer was quantified for each condition using seven
confocal sections processed with NIH Image J for signal
analysis. Pax6 staining was quantified only in GFP posi-
tive cells (HeLa cells) in order to exclude signal from
transfected COS cells.
Fish embryo manipulation
Zebrafish (Danio rerio) were raised and staged according
to [57]. RNA for single-chain antibodies transcribed in
vitro from their linearized templates with the mMessage
mMachine T7 kit (Ambion, Austin, USA)) were injected at
a concentration of 100 ng/ml. Quantitative analysis of
mRNA efficiency was performed on 50 microinjected
embryos, manually dechorionated and freed from vitellus
at the beginning of gastrulation, lysed in Laemmli buffer
and electophoresed on a 12% SDS-polyacrylamide gel.
Myc-tagged single-chain antibodies were detected on
western blots with the 9E10 monoclonal anti-myc anti-
body (DSHB) and electrochimioluminescence (ECL,
Amersham, Amersham Place, UK), and signal quantifica-
tion was performed using Image J software. Hybridoma
supernatants (anti-Pax6 and 9E10 anti-myc, DSHB) and
FITC-anti-mouse IgG (Jackson ImmunoResearch, New
Market, UK) were injected at mid-blastula stage according
to Minchiotti and colleagues [58] at a concentration of 40
μg/ml.
In situ hybridization, immunohistochemistry and 
morphometric analysis in zebrafish
Whole mount in situ hybridization and immunohisto-
chemistry were performed according to standard proto-
cols [59]. RNA probes were prepared from Pax6a (NotI,
T7) and pCS2RX3 (HindIII, T7; a gift from Dr Laure Bally-
Cuif, GSF, Neuherberg, Germany). Anti-myc antibodies
were from DSHB (monoclonal 9E10) or Upstate Biotech-
nology (Charlottesville, USA) (polyclonal) and all sec-
ondary antibodies from Amersham. Embryos were
embedded in 7.5% gelatin, 15% sucrose, 20 mM phos-
phate buffer pH 7.4, and frozen sections (14 μm) were
mounted in 75% glycerol. Morphometric analysis was
performed using Lucia G image-processing and analysis
software (Version 4.61, Nikon, Kingston upon Thames,
UK). All eyes were measured (arbitrary units) and individ-
ual measures were distributed among 12 size classes
(8.3% increment steps), class 1 corresponding to the
smallest eyes (as in Figure 3e).
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